Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses

Jennifer G. Robinson, Michel Farnier, John J. P. Kastelein, Eli M. Roth, Marja-Riitta Taskinen, Helen M. Colhoun, Aurelie Brunet, A. Thomas DiCioccio, Guillaume Lecorps, Robert Pordy, Marie T. Baccara-Dinet, Christopher P. Cannon

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalJournal of Clinical Lipidology
Volume13
Issue number6
Pages (from-to)979-988
Number of pages10
ISSN1933-2874
DOIs
Publication statusPublished - Dec 2019
MoE publication typeA1 Journal article-refereed

Fields of Science

  • PCSK9
  • Low-density lipoprotein cholesterol
  • Monoclonal antibody
  • Cardiovascular
  • Clinical trial
  • Pharmacokinetic
  • CARDIOVASCULAR-RISK PATIENTS
  • HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
  • MONOCLONAL-ANTIBODY
  • INHIBITOR ALIROCUMAB
  • ADD-ON
  • EFFICACY
  • SAFETY
  • ATORVASTATIN
  • MONOTHERAPY
  • EZETIMIBE
  • 317 Pharmacy

Cite this